IPOPI has welcomed the positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The opinion recommends granting marketing authorisation in the European Union for Waskyra™, a groundbreaking ex vivo gene therapy for Wiskott-Aldrich Syndrome (WAS), a rare and life-threatening primary immunodeficiency. “This marks a significant milestone […]
In 2024, IPOPI continued to bring the global PID community together — connecting patients, experts, and advocates across 75 countries to improve lives and drive progress in care and diagnosis for people with primary immunodeficiencies (PIDs). Highlights included the XVIII Global Patients’ Meeting in Marseille, new advocacy initiatives on plasma access and newborn screening, and […]
The IPOPI Jose Drabwell Research Grant Programme is an initiative aimed at promoting scientific and clinical research in the field of primary immunodeficiencies. The second grant call in 2025, supported by Grifols and Kedrion, ran from April to August, inviting applicants from around the world to seize the opportunity to fuel innovation in the field […]
From 16-19 October, IPOPI’s XVIII Global Patients’ Meeting (GPM) brought together 100 participants from nearly 50 countries, in Marseille, marking a record number of National Member Organisations (NMOs). Held alongside the European Society for Immunodeficiencies (ESID) and the International Nursing Group for Immunodeficiencies’ (INGID) congresses, this flagship biennial event highlighted collaboration across the primary immunodeficiency (PID) community. Programme This meeting featured insightful sessions on mental health, innovative therapies, artificial […]
The proceedings of the third Global Multi-Stakeholders Summit held by IPOPI on July 1-2, 2024, in Lisbon, Portugal, have been published in Frontiers in Immunology. The paper entitled “Navigating disruption in the PID landscape: embracing opportunities and anticipating threats in the next ten years” reflects the high-level discussions held over the two-day summit between all participants. Participants […]
